AUC values were higher than 0.75 in two anti-PD-1 treatments and one anti-PD-1/anti-CTLA-4 (Fig. 4I), suggesting that IRS is relevant for predicting sensitivity to immunotherapy in patients with gastric cancer. This evidence concerns the gene CTLA4 and gastric cancer.